Sage Therapeutics Inc
(FRA:SG7)
€
5.452
0.102 (1.91%)
Market Cap: 325.18 Mil
Enterprise Value: -211.07 Mil
PE Ratio: 0
PB Ratio: 0.61
GF Score: 49/100 SAGE Therapeutics Inc at Cowen Health Care Conference (Virtual) Transcript
Mar 07, 2022 / 03:30PM GMT
Release Date Price:
€30.79
(-1.94%)
Ritu Subhalaksmi Baral
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst
Good morning, everyone. Thanks for joining us at the Cowen Healthcare Conference for the fireside chat with Sage Therapeutics. I'm covering analyst, Ritu Baral. And joining us today from Sage is CEO, Barry Greene. Barry. Thanks for joining us this morning.
Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director
Thanks, Ritu, and thanks Cowen for having us. Appreciate it.
Questions & Answers
Ritu Subhalaksmi Baral
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst
Of course. Lots going on. We've got 30 minutes. So I want to be able to hit on those topics of most intense investor focus as I've seen them in my investor calls recently. The first issue is the zuranolone MDD filing. Now that you have CORAL successfully behind you, statistical significance, it doesn't look like there's anything there that is necessarily going to be problematic for the filing.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot